
S3-E25.4 – NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.